Michael C. Milone, MD, PhD
Pathology and Laboratory Medicine
Sees patients age 18 and up
Penn Pathology and Laboratory Medicine HUP
Headshot of Michael C. Milone, MD, PhD
Penn Medicine Provider

About me

  • Associate Director, Toxicology Laboratory
  • Associate Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania

My clinical expertise is in Clinical Laboratory Toxicology, Therapeutic Drug Monitoring, Clinical Chemistry, Blood Banking/Transfusion Medicine, Therapeutic Apheresis.

Education and training

  • Medical School: University of Medicine and Dentistry of New Jersey
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania School of Medicine

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Pennsylvania Hospital: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Milone is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

My research

Liu, S., Guruprasad, P., Ramasubramanian, R., Madhu, B., Paruzzo, L., Han, K., Kelly, A., Shestov, A., Xu, H. N., Carturan, A., Zhou, C., Amses, K. R., Afriat, A., Litichevskiy, L., Lin, J., Dubowitz, E., Tangal, N., Zhang, J., McSween, A., Tan, M., Stella, F., Lee, A., Nason, S., Hua, X., Schneider, M., Sleeman, M., Zhang, Y., Gabrielli, G., Yang, Z., Pajarillo, R., Patel, R., Ghilardi, G., Patel, V., Joshi, A., Jiang, S., Jiang, Y., Porazzi, P., Tchou, J. C., Keith, B., Li, M., Chong, E., Schuster, S. J., Milone, M., Rabinowitz, J., O'Connor, R. S., Thaiss, C. A., Levy, M., Ruella, M. β-hydroxybutyrate enhances the metabolic fitness of CAR T cells in cancer , Cell: 2026


Engel NW, Steinfeld I, Ryan D, Anupindi K, Kim S, Wellhausen N, Chen L, Wilkins K, Baker DJ, Rommel PC, Jarocha D, Gohil M, Zhang Q, Milone MC, Fraietta JA, Davis M, Young RM, June CH. Quadruple adenine base-edited allogeneic CAR T cells outperform CRISPR/Cas9 nuclease-engineered T cells , Proc Natl Acad Sci U S A, 122: 2025,e2427216122


Balis FM, Rieger E, Bunin NJ, Gardiner J, Shaw LM, Olson TS, Milone MC. New approach to busulfan dosing in infants and children based on a population pharmacokinetic analysis , Cancer Chemother Pharmacol, 95: 2025,32


Zhang, Qian, Wu, Yihao, Yang, Jingyi, Zhou, Kevin, Anand Manoharan, Eric Nigel Ebenezer, Wentz, Tyra, Su, Leon, Yu, Alvin, Wang, Hong-Yi, Bruhn, Laurakay, Steinfeld, Israel, Gonzalez, Nicolas, Song, Edward Z., Zhang, Yunlin, Hresko, Morgan E., Ryan, Daniel E., Engel, Nils W., Nunez-Cruz, Selene, June, Carl H., Garcia, K. Christopher, Milone, Michael C. Viral vector-free generation of orthogonal IL-2–responsive CAR T cells through gene editing of IL-2 and its receptor , Blood Immunology & Cellular Therapy, 1(3): 2025


Ghilardi, G., Paruzzo, L., Svoboda, J., Chong, E. A., Shestov, A. A., Chen, L., Cohen, I. J., Gabrielli, G., Nasta, S. D., Porazzi, P., Landsburg, D. J., Gerson, J. N., Carter, J., Barta, S. K., Yelton, R., Pajarillo, R., Patel, V., White, G., Ballard, H. J., Weber, E., Napier, E., Chong, E. R., Fraietta, J. A., Garfall, A. L., Porter, D. L., Milone, M. C., O'Connor, R., Schuster, S. J., Ruella, M. Bendamustine lymphodepletion before axicabtagene ciloleucel is safe and associates with reduced inflammatory cytokines , Blood Adv, 8(3): 2024,653-666


Zhang Z, Markmann C, Yu M, Agarwal D, Rostami S, Wang W, Liu C, Zhao H, Ochoa T, Parvathaneni K, Xu X, Li E, Gonzalez V, Khadka R, Hoffmann J, Knox JJ, Scholler J, Marcellus B, Allman D, Fraietta JA, Samelson-Jones B, Milone MC, Monos D, Garfall AL, Naji A, Bhoj VG. Immunotherapy targeting B cells and long-lived plasma cells effectively eliminates pre-existing donor-specific allo-antibodies , Cell Rep Med, 4: 2023,101336


Grover P, Nunez-Cruz S, Leferovich J, Wentz T, Bagchi A, Milone MC, Greene MI. F77 antigen is a promising target for adoptive T cell therapy of prostate cancer , Biochem Biophys Res Commun, 680: 2023,51-60


Oh S, Mao X, Manfredo-Vieira S, Lee J, Patel D, Choi EJ, Alvarado A, Cottman-Thomas E, Maseda D, Tsao PY, Ellebrecht CT, Khella SL, Richman DP, O'Connor KC, Herzberg U, Binder GK, Milone MC, Basu S, Payne AS. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells , Nat Biotechnol, 41(9): 2023,1229-1238


Glisovic-Aplenc, T., Diorio, C., Chukinas, J. A., Veliz, K., Shestova, O., Shen, F., Nunez-Cruz, S., Vincent, T. L., Miao, F., Milone, M. C., June, C. H., Teachey, D. T., Tasian, S. K., Aplenc, R., Gill, S. CD38 as a pan-hematologic target for chimeric antigen receptor T cells , Blood Adv, 7(16): 2023,4418-4430


Thakrar AP, Faude S, Perrone J, Milone MC, Lowenstein M, Snider CK, Spadaro A, Delgado MK, Nelson LS, Kilaru AS. Association of Urine Fentanyl Concentration With Severity of Opioid Withdrawal Among Patients Presenting to the Emergency Department , J Addict Med, 17(4): 2023,447-453


View all publications